Eisai Co., Ltd. and Biogen Inc. announced on January 6th that under the Accelerated Approval Pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb, which has the brand name in the United States of LEQEMBITM, for the treatment of Alzheimer’s disease. The approval is based on Phase 2 data that demonstrated that LEQEMBI reduced the accumulation of Aβ plaque in the brain, a defining feature of Alzheimer’s disease. Newt’s guest is Dr. Marwan Sabbagh, MD. He is a behavioral neurologist in the Alzheimer’s and Memory Disorders Program and a professor in the Department of Neurology at Barrow Neurological Institute and was one of the leading doctors of the study.
See omnystudio.com/listener for privacy information.
Episode 704: Election 2024 – State of the Race
Episode 703: What’s Next for Iran?
Episode 702: Lessons in Liberty
Episode 701: Woke Warriors
Episode 700: U.S. National Security
Episode 699: Teacher Morale
Episode 698: Platon on The Defenders
Episode 697: The Culture War on the American Family
Episode 696: The New Space Race – United States vs. China
Episode 695: Nuclear War: A Scenario
Episode 694: Defeating Hamas in Rafah
Episode 693: Emperor Penguin Chicks Jump Off a 50 Foot Ice Shelf
Episode 692: Governor Reagan on College Protests
Episode 691: The Power of A.I. – An Overview
Episode 690: Wall Street’s War on Workers
Episode 689: Family Unfriendly
Episode 688: Artificial Intelligence Policy
Episode 687: Reforming the Criminal Justice System
Episode 686: Iran Attacks Israel
Episode 685: Welfare Reform
Create your
podcast in
minutes
It is Free